The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

Mireia Raluy-Callado, Wen-Hung Chen, David A H Whiteman, Juanzhi Fang, Ingela Wiklund, Mireia Raluy-Callado, Wen-Hung Chen, David A H Whiteman, Juanzhi Fang, Ingela Wiklund

Abstract

Background: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was to describe this impact using the Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire and a range of standard validated questionnaires previously used in paediatric populations.

Methods: Clinical and demographic characteristics collected in a clinical trial and responses to four HRQL questionnaires completed both by patients and parents prior to enzyme replacement treatment were used. The association between questionnaire scores and clinical function parameters were tested using Spearman rank-order correlations. Results were compared to scores in other paediatric populations with chronic conditions obtained through a targeted literature search of published studies.

Results: Overall, 96 male patients with MPS II and their parents were enrolled in the trial. All parents completed the questionnaires and 53 patients above 12 years old also completed the self-reported versions. Parents' and patients' responses were analysed separately and results were very similar. Dysfunction according to the HS-FOCUS and the CHAQ was most pronounced in the physical function domains. Very low scores were reported in the Self Esteem and Family Cohesion domains in the CHQ and HUI3 disutility values indicated a moderate impact. Scores reported by patients and their parents were consistently lower than scores in the other paediatric populations identified (except the parent-reported Behaviour score); and considerably lower than normative values.

Conclusions: This study describes the impact on HRQL in patients with MPS II and provides a broader context by comparing it with that of other chronic paediatric diseases. Physical function and the ability to perform day-to-day activities were the most affected areas and a considerable impact on the psychological aspects of patients' HRQL was also found, with a higher level of impairment across most dimensions (particularly Pain and Self Esteem) than that of other paediatric populations. Such humanistic data provide increasingly important support for establishing priorities for health care spending, and as a component of health economic analysis.

Trial registration: ClinicalTrials.gov NCT00069641.

Figures

Figure 1
Figure 1
Patient-reported CHQ-CF87 scores compared with scores in a diabetic population.
Figure 2
Figure 2
Caregiver-reported CHQ-PF50 scores compared with proxy-reported scores in other paediatric populations and with proxy-reported normative values.
Figure 3
Figure 3
Caregiver-reported HUI3 utility values compared with caregiver-reported scores in other paediatric populations.

References

    1. Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Marti-Herrero M, Munguira-Aguado P, Galan-Gomez E. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS) Eur J Med Genet. 2010;53:371–377. doi: 10.1016/j.ejmg.2010.07.013.
    1. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101:355–358. doi: 10.1007/s004390050641.
    1. Young ID, Harper PS. Mild form of Hunter’s syndrome: clinical delineation based on 31 cases. Arch Dis Child. 1982;57:828–836. doi: 10.1136/adc.57.11.828.
    1. Young ID, Harper PS. The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev Med Child Neurol. 1983;25:481–489.
    1. Pascolini D, Smith A. Hearing Impairment in 2008: a compilation of available epidemiological studies. Int J Audiol. 2009;48:473–485. doi: 10.1080/14992020902803120.
    1. WHO ear and hearing disorders survey protocol for a population-based survey of prevalence and causes of deafness and hearing impairment and other ear disorders. [ ]
    1. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M. et al.Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95–101. doi: 10.1097/GIM.0b013e3181fea459.
    1. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome) Mol Genet Metab. 2007;90:329–337. doi: 10.1016/j.ymgme.2006.09.001.
    1. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M. et al.A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet Med. 2006;8:465–473. doi: 10.1097/01.gim.0000232477.37660.fb.
    1. da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome) Cochrane Database Syst Rev. 2011;11:CD008185.
    1. Needham MC, Packman W, Packman W, Packman S. Adaptive functioning and health-related quality of life of patients with mucopolysaccharidosis type ii (hunter syndrome) Mol Genet Metab. 2012;105:344.
    1. Kunin-Batson A, Erickson N, Ahmed A, Yund B, Sharipo E. Quality of life after treatment for mucopolysaccharidoses. Mol Genet Metab. 2012;105:S42.
    1. Shire Human Genetic Therapies, Inc. [Internet] Bethesda (MD): National Library of Medicine (US); 2000. A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II. [cited 2013 Jan 15]. Available from: NLM Identifier: NCT00069641.
    1. Wiklund I, Raluy-Callado M, Stull DE, Jangelind Y, Whiteman DA, Chen WH. The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire: evaluation of measurement properties. Qual Life Res. 2013;22:874–884.
    1. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209.
    1. Landgraf JM, Abetz LN, Ware JE. The CHQ User’s Manual. Boston: The Health Institute, New England Medical Center; 1999.
    1. Valayannopoulos V, de Blic J, Mahlaoui N, Stos B, Jaubert F, Bonnet D, Fischer A, de Lonlay P. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Pediatrics. 2010;126:e1242–e1247. doi: 10.1542/peds.2009-2843.
    1. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54. doi: 10.1186/1477-7525-1-54.
    1. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, Cate RT, Koopman-Keemink Y, van Santen-Hoeufft M, Raat H, van Suijlekom-Smit LW. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2010;69:138–142. doi: 10.1136/ard.2009.111260.
    1. Daltroy LH, Liang MH, Fossel AH, Goldberg MJ. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. J Pediatr Orthop. 1998;18:561–571.
    1. Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab. 2006;88:208–215. doi: 10.1016/j.ymgme.2006.01.010.
    1. Keith RA, Granger CV, Hamilton BB, Sherwin FS. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil. 1987;1:6–18.
    1. Peck JE. Hearing loss in Hunter’s syndrome–mucopolysaccharidosis II. Ear Hear. 1984;5:243–246.
    1. Asmussen L, Olson LM, Grant EN, Landgraf JM, Fagan J, Weiss KB. Use of the child health questionnaire in a sample of moderate and low-income inner-city children with asthma. Am J Respir Crit Care Med. 2000;162:1215–1221. doi: 10.1164/ajrccm.162.4.2001067.
    1. Keilmann A, Nakarat T, Bruce IA, Molter D, Malm G. on behalf of the HOS Investigators. Hearing Loss in Patients With Mucopolysaccharidosis II: Data From HOS – the Hunter Outcome Survey. J Inherit Metab Dis. 2012;35:343–353. doi: 10.1007/s10545-011-9378-5.
    1. Trzesniewski KH, Donnellan MB, Moffitt TE, Robins RW, Poulton R, Caspi A. Low self-esteem during adolescence predicts poor health, criminal behavior, and limited economic prospects during adulthood. Dev Psychol. 2006;42:381–390.
    1. Bullinger M, Mackensen SV, Langraf J. Assessing the quality of life of children. Qual Life Res. 1994;3:41.
    1. Guyatt GH, Juniper EF, Griffith LE, Feeny DH, Ferrie PJ. Children and adult perceptions of childhood asthma. Pediatrics. 1997;99:165–168. doi: 10.1542/peds.99.2.165.
    1. Brunner HI, Maker D, Grundland B, Young NL, Blanchette V, Stain AM, Feldman BM. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs) Med Decis Making. 2003;23:314–322. doi: 10.1177/0272989X03256008.
    1. Erling A, Wiklund I, Albertsson-Wikland K. Prepubertal children with short stature have a different perception of their well-being and stature than their parents. Qual Life Res. 1994;3:425–429. doi: 10.1007/BF00435394.
    1. Banks BA, Barrowman NJ, Klaassen R. Health-related quality of life: changes in children undergoing chemotherapy. J Pediatr Hematol Oncol. 2008;30:292–297. doi: 10.1097/MPH.0b013e3181647bda.
    1. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440. doi: 10.1378/chest.121.5.1434.
    1. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:822–832. doi: 10.1183/09031936.06.00145104.
    1. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillen-Navarro E, Hensman P, Jones S. et al.Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72. doi: 10.1186/1750-1172-6-72.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다